Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Acyclic nitrogen double bonded to acyclic nitrogen – acyclic...
Patent
1994-02-28
1995-11-21
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...
435 724, 4352402, G01N 100
Patent
active
054684692
ABSTRACT:
Pharmaceutical compositions containing the azo dyes Direct Orange 26, Direct Red 23, Direct Red 24, Direct Red 26, and similar dyes, as well as the use of such azo dyes to inhibit the binding of a virus to the CD4 glycoprotein, in detecting or quantitating CD4-positive T4 lymphocytes, and in the protection against or treatment of viral infections.
REFERENCES:
patent: 662122 (1900-11-01), Israel et al.
patent: 663498 (1900-12-01), Israel et al
Alarcon et al., Antiviral Research, 4, 231-243 (1984).
Anand et al., Antimicrobial Agents and Chemotherapy, 32(5), 684-688 (May 1988).
Anand et al., Antiviral Chemistry & Chemotherapy, 1(1), 41-46 (1990).
Cushman et al., J. Med. Chem., 34, 337-342 (1991).
Lifson et al., Science, 241, 712-716 (Aug. 5, 1988).
Smith et al., Science, 238, 1704-1707 (Dec. 18, 1987).
.ANG.kerfeldt et al., "Aromatic Sulfonic Acids as Viral Inhibitors. Structure-Activity Study using Rhino, Adeno 3, Herpes Simplex, and Influenza Viruses," J. Medicin. Chem., 14(7), 596-600 (1971).
Anand et al., "Sodium Pentosan Polysulfate (PPS), an Anti-HIV Agent Also Exhibits Synergism with AZT, Lymphoproliferative Activity,a nd Virus Enhancement," AIDS Res. Human Retrovir., 6, 679-689 (1990).
Balzarini et al., "Aurintricarboxylic Acid and Evans Blue Represent Two Different Classes of Anionic Compounds Which Selectively Inhibit the Cytopathogenicity of Human T-Cell Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus," Biochem. Biophys. Res. Commun., 136, 64-71 (1986).
Balzarini et al., "Comparative Inhibitory Effects of Suramin and Other Selected Compounds on the Infectivity and Replication of Human T-Cell Lymphotropic Virus (HTLV-III)/Lymphadenopathy-Associated Virus (LAV)," Int. J. Cancer, 37, 451-457 (1986).
Cushman et al., "Preparation and Anti-HIV Activities of Aurintricarboxylic Acid Fractions and Analogues: Direct Correlation of Antiviral Potency with Molecular Weight," J. Med. Chem., 34, 329-337 (1991).
Hurst et al., "The Prevention of Encephalitis Due To The Viruses of Eastern Equine Encephalomyelitis and Louping-Ill: Experiments with Trypan Red, Mepacrine, and Many Other Substances," Brit. J. Pharmacol., 7, 455-472 (1952).
Mohan et al., "Potential Anti-AIDS Agents. Synthesis and Antiviral Activity of Naphthalenesulfonic Acid Derivatives against HIV-1 and HIV-2," J. Med. Chem., 34, 212-217 (1991).
Pal et al., "Comparative Effects of Polyanionic Compounds on Syncytia Formation and Infectivity of Human Immunodeficiency Virus Type I and Type II," Aids Res. Human Retrovir., 7, 133 (1991).
Thorne et al., "Inactivation of Measles and Herpes Simplex Viruses by Trypan Blue," J. Gen. Virol., 64, 1365-1368 (1983).
Weaver et al., "Polyionic Compounds Selectively Alter Availability of CD4 Receptors for HIV Coat Protein rgp120," AIDS Res. Human Retrovir., 6, 1125-1130 (1990).
Weaver et al., "Inhibition of the binding of HIV rgp120 to CD4 by dyes," Antiviral Chem. & Chemotherapy, 3(3), 147-151 (1992).
Aszalos Adorjan
Pine P. Scott
Weaver James L.
The United States of America as represented by the Department of
Travers Russell
LandOfFree
Methods of using azo dyes and their derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using azo dyes and their derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using azo dyes and their derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1135171